当前位置:
X-MOL 学术
›
Sustainability
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Trends of Business-to-Business Transactions to Develop Innovative Cancer Drugs
Sustainability ( IF 3.9 ) Pub Date : 2020-07-09 , DOI: 10.3390/su12145535 Arisa Djurian , Tomohiro Makino , Yeongjoo Lim , Shintaro Sengoku , Kota Kodama
Sustainability ( IF 3.9 ) Pub Date : 2020-07-09 , DOI: 10.3390/su12145535 Arisa Djurian , Tomohiro Makino , Yeongjoo Lim , Shintaro Sengoku , Kota Kodama
A key concept in the pharmaceutical industry is open innovation, in which pharmaceutical companies contribute to human health and adapt to a changing business environment by acquiring external knowledge. As successful drug discoveries and developments have become challenging, pharmaceutical companies must proactively pursue the open innovation of new drugs through various inter-firm partnerships to be more sustainable. This study aims to interpret the trend of inter-firm partnerships in the development of cancer drugs and to evaluate their effectiveness by examining inter-firm transactions related to cancer drugs approved by the US Food and Drug Administration (FDA). It is a novel approach to exercise this on each product instead of at the company level. The findings revealed that the number of inter-firm transactions in the oncology field has increased over the past 20 years. Furthermore, the annual number of transactions related to biologics has surpassed that of small molecules since 2015 and has been primarily driven by three PD-(L)1 inhibitors: Keytruda, Opdivo, and Tecentriq. Moreover, the average number of inter-firm transactions related to biologics is significantly higher than that of small molecules in total, in alliances, and in financing, suggesting that inter-firm transactions for biologic cancer drugs actively occur through various means. Additionally, a positive and significant correlation exists between the number of transactions and the average number of approved indications for biologics, but not for small molecules. These results suggest that the observed trend of active inter-firm transactions is key in increasing the probability of success in cancer drug research and development. This could provide a potential breakthrough in this industry for the successful development of innovative drug candidates to address unmet medical needs. Further study is necessary to confirm the applicability of this paradigm in broader drug discoveries and development.
中文翻译:
开发创新抗癌药物的企业对企业交易趋势
制药行业的一个关键概念是开放式创新,即制药公司通过获取外部知识为人类健康做出贡献并适应不断变化的商业环境。随着成功的药物发现和开发变得具有挑战性,制药公司必须通过各种公司间合作伙伴关系积极追求新药的开放式创新,以提高可持续性。本研究旨在通过检查与美国食品和药物管理局 (FDA) 批准的抗癌药物相关的公司间交易来解释公司间合作伙伴关系在抗癌药物开发中的趋势并评估其有效性。这是一种在每个产品上而不是在公司级别上执行此操作的新颖方法。调查结果显示,在过去 20 年中,肿瘤学领域的公司间交易数量有所增加。此外,自 2015 年以来,与生物制剂相关的年度交易数量已超过小分子,主要由三种 PD-(L)1 抑制剂驱动:Keytruda、Opdivo 和 Tecentriq。此外,生物药相关企业间交易的平均数量在总量、联盟和融资方面均显着高于小分子,表明生物抗癌药物的企业间交易通过各种方式活跃地发生。此外,交易数量与生物制剂批准适应症的平均数量之间存在显着的正相关,但对于小分子则不然。这些结果表明,观察到的活跃的公司间交易趋势是增加抗癌药物研发成功概率的关键。这可以为该行业的成功开发创新候选药物以解决未满足的医疗需求提供潜在的突破。需要进一步研究以确认这种范式在更广泛的药物发现和开发中的适用性。
更新日期:2020-07-09
中文翻译:
开发创新抗癌药物的企业对企业交易趋势
制药行业的一个关键概念是开放式创新,即制药公司通过获取外部知识为人类健康做出贡献并适应不断变化的商业环境。随着成功的药物发现和开发变得具有挑战性,制药公司必须通过各种公司间合作伙伴关系积极追求新药的开放式创新,以提高可持续性。本研究旨在通过检查与美国食品和药物管理局 (FDA) 批准的抗癌药物相关的公司间交易来解释公司间合作伙伴关系在抗癌药物开发中的趋势并评估其有效性。这是一种在每个产品上而不是在公司级别上执行此操作的新颖方法。调查结果显示,在过去 20 年中,肿瘤学领域的公司间交易数量有所增加。此外,自 2015 年以来,与生物制剂相关的年度交易数量已超过小分子,主要由三种 PD-(L)1 抑制剂驱动:Keytruda、Opdivo 和 Tecentriq。此外,生物药相关企业间交易的平均数量在总量、联盟和融资方面均显着高于小分子,表明生物抗癌药物的企业间交易通过各种方式活跃地发生。此外,交易数量与生物制剂批准适应症的平均数量之间存在显着的正相关,但对于小分子则不然。这些结果表明,观察到的活跃的公司间交易趋势是增加抗癌药物研发成功概率的关键。这可以为该行业的成功开发创新候选药物以解决未满足的医疗需求提供潜在的突破。需要进一步研究以确认这种范式在更广泛的药物发现和开发中的适用性。